PMID: 1459138Dec 1, 1992

Molecular mimicry of trifluoroacetylated human liver protein adducts by constitutive proteins and immunochemical evidence for its impairment in halothane hepatitis

European Journal of Biochemistry
J GutJ G Kenna


A monospecific antibody (anti-CF3CO antibody) was obtained by affinity chromatography on a N epsilon-trifluoroacetyl-L-lysine (CF3CO-Lys) matrix of a rabbit polyclonal antiserum, directed against trifluoroacetylated protein adducts (CF3CO-proteins). The anti-CF3CO antibody recognized distinct CF3CO-proteins on immunoblots of a liver biopsy obtained from a human individual 10 h after halothane anaesthesia. Cross-reactive proteins of 52 kDa and 64 kDa were recognized on immunoblots of livers obtained from human individuals not exposed to halothane. Recognition of both CF3CO-proteins and the 52-kDa and 64-kDa cross-reactive proteins was abolished in the presence of 1 mM CF3CO-Lys. Anti-CF3CO antibody, affinity-adsorbed to the 52-kDa or the 64-kDa cross-reactive proteins of human liver, recognized the majority of target CF3CO-proteins on immunoblots of the human liver biopsy of an individual exposed to halothane. Liver biopsies of 5 out of 7 (71%) patients with halothane hepatitis exhibited an absence or low amounts of immunorecognizable 52-kDa and/or 64-kDa cross-reactive proteins. In contrast, of 22 control human individuals tested, all liver tissue samples were positive for the 52-kDa and/or the 64-kDa cross-reactive proteins. T...Continue Reading


Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Jan 1, 1991·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R H Moseley
Feb 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·J W HarrisM W Anders
Feb 28, 1991·Biochemical and Biophysical Research Communications·U ChristenJ Gut
Feb 1, 1991·Biochemical Society Transactions·J G Kenna
Jun 15, 1990·Science·R H Schwartz
Jan 1, 1987·International Journal of Immunopharmacology·J NeubergerR Williams
Apr 1, 1989·The British Journal of Surgery·A A Gunn
Jan 1, 1989·Drug Metabolism Reviews·L R PohlJ L Martin
Jan 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·H SatohL R Pohl
Nov 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J G KennaR Williams
Apr 24, 1987·Cell·J W KapplerP Marrack
Dec 1, 1987·Anesthesia and Analgesia·M Siadat-PajouhA J Gandolfi


May 1, 1994·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Y SakaguchiS Takahashi
May 14, 1999·European Journal of Drug Metabolism and Pharmacokinetics·P M DansetteD Mansuy
Jan 1, 1993·Pharmacology & Therapeutics·J GutJ Huwyler
Nov 27, 1999·Molecular Aspects of Medicine·J A Hasler
Jan 1, 1997·Journal of Hepatology·P H Beaune, S Lecoeur
Jun 23, 1993·Annals of the New York Academy of Sciences·J G KennaF N van Pelt
Sep 1, 1996·Baillière's Clinical Gastroenterology·P Obermayer-Straub, M P Manns
Jan 1, 1997·Journal of Hepatology·J G Kenna
Jan 1, 1995·Critical Reviews in Toxicology·U A BoelsterliA Kretz-Rommel
Jan 13, 2016·World Journal of Gastroenterology : WJG·Jinjun WangPatrick S C Leung
Dec 1, 1995·Anesthesia and Analgesia·J G Kenna, R M Jones

Related Concepts

Immunoblotting, Reverse
Rats, Holtzman
Drug-Induced Acute Liver Injury

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.